Navigation Links
Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
Date:10/27/2008

KANSAS CITY, Mo., Oct. 27 /PRNewswire/ -- Thomas Reidy, an investor in Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts are traded on NASDAQ, will host an investor conference call November 3, 2008, at 10:00am EST, to discuss the recent shareholder proposal calling for the removal and replacement of Trinity Biotech's current directors.

On October 16, 2008, Mr. Reidy, and nine other shareholders, sent a letter to Trinity Biotech requesting that a special meeting of shareholders be held to consider the immediate removal of the current directors of Trinity Biotech. In the same letter, the investor group, who collectively hold beneficial ownership of more than 10% of Trinity Biotech's voting stock, directed that Trinity Biotech shareholders be given the opportunity to vote on the following slate of replacement directors:

-- Dr. Jack C. Chow, M.D., M.B.A. -- Partner, CRV Capital, LLC and adjunct

professor at Carnegie Mellon University's Heinz School of Public Policy

and Management;

-- Mr. Mike Gausling -- Managing Partner, Originate Ventures;

-- Dr. John H. Halsey, Ph.D. -- Chief Executive Officer, Director,

Founder, ProGene Biomedical, Inc. (dba IBT Laboratories);

-- Mr. Steven A. Mock, CPA -- Partner, BKD, LLP;

-- Mr. Thomas Reidy; and

-- Mr. Clint Severson -- Chairman, President and CEO of Abaxis, Inc.

According to Irish Law, Trinity Biotech must call a special meeting of shareholders, called an Extraordinary General Meeting, if the meeting is requested by shareholders holding in excess of 10% of the voting paid-up capital of the company.

The purpose of the conference call will be to provide Trinity Biotech shareholders information regarding the reasons for the proposal, the company's response to the proposal, if any, the qualifications of the replacement directors, and steps that shareholders can take to impose accountability on company management.

The conference call can be accessed in the U.S. by dialing 1-800-899-9949 conference code 2111155.

Thomas J. Reidy, Kansas City, (816) 260-8476


'/>"/>
SOURCE Thomas J. Reidy, Kansas City
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
2. GenVault to Present at the BIOCOM Investor Conference
3. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
4. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
5. BioAtom Inc. To Present at BIOCOM Investor Conference 2008
6. Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum
7. Oncothyreon to present at BIO Investor Forum 2008
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
Breaking Biology News(10 mins):